Surveillance Study of NovoRapid® for New Drug Re-examination

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 1; Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: insulin aspart

Study type: Observational

Funder types: Industry

Identifiers

NCT01490112

ANA-1881

Details and patient eligibility

About

This study is conducted in Asia. The aim of this study is to observe the safety and efficacy of insulin aspart (NovoRapid®) administered via vial and three different devices.

Enrollment: 1,239 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Subjects with diabetes mellitus (type 1, type 2, or gestational) prescribed with insulin aspart (NovoRapid®)

Trial design

1,239 participants in 1 patient group

IAsp

Treatment:

Drug: insulin aspart